Company profile

NexMR AG

NexMR aims to deliver fully characterized hits to support drug discovery pipelines. Thanks to our proprietary technology using sensitivity-enhanced NMR we can screen libraries of thousands of molecules within days. We are also able to characterize the hits without idle time, as our technology encompasses affinity and structure determination. Contrary to state-of-the-art methods (X-ray crystallography, surface plasmon resonance), we only require minimal assay development, allowing us to screen challenging targets which were not addressed so far. The sample conditions used in NMR are milder and closer to physiological conditions than for other techniques, therefore facilitating the transition to further development.

More news about NexMR AG

11.11.2024 09:00

Strong startup delegation at Medica 2024

Please login or
register to use the
awards follow feature
06.09.2024 12:00

Kickfund invests at full throttle

Please login or
register to use the
awards follow feature
25.01.2024 14:35

ZKB Pionierpreis Technopark shortlists 11 startups

Please login or
register to use the
awards follow feature
23.12.2022 12:00

NexMR secures funds to accelerate drug discovery

Please login or
register to use the
awards follow feature
NexMR AG

Founded
2022

Kanton
Zürich


LinkedIn

Homepage

rss